TYR and melanoma: Choi et al. [90] reported that when thymol was treated in mouse-derived melanoma cells (B16F10 melanoma cells), more than 80% of cell viability was maintained up to 200 μM concentration as well as inhibiting the expression of tyrosinase by α-MSH stimulation.